| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185788 | Gynecologic Oncology | 2013 | 9 Pages |
Abstract
⺠Gefitinib was evaluated in a phase II trial of advanced endometrial cancer. ⺠One patient achieved a complete response, though gefitinib did not demonstrate significant clinical activity overall. ⺠The levels of a soluble truncated form of EGFR, sEGFR, positively correlated with overall survival.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robert S. Mannel, Krishnansu S. Tewari, Parviz Hanjani, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle,